Intuition’s Lung Density Analysis II workflow delivers newly enhanced segmentation data science and automated measurementcapabilities within a guided workflow for the disease progression assessment and quantification of COVID-19 and lung related illness.*
Improving Patient Outcomes through AI-driven Insights
Achieve faster and better-informed care leveraging purpose built and easy-to-consume interpretation solutions.
Strengthen clinical decision making and diagnosis with AI-driven imaging insights in immersive and intuitive dashboards.
Increase confidence by using technology noted as the ground truth for accuracy and precision in advanced image processing.
Fast Access to Lung Quantification Results & Tissue Characterization
Current lung quantification and segmentation workflows are not specific to recent unique disease presentation.
Physicians need a fast way to identify affected lung tissue and viable lung capacity of infected patients.
Physicians can more quickly & effectively identify disease impact, determine progression or improvement, and suggest additional or follow-up treatment required for better patient outcomes.
Lung Density Analysis II Key Features
By leveraging Intuition's capabilities in lung segmentation, volumetric histogram analysis and automation, physicians can quickly analyze and quantify lung tissue with little to no manual intervention.
Take a Step-by-Step Tour
Lung Density Analysis II (LDA-II) for Intuition provides enhanced segmentation and a customized workflow for lung assessment that may be applied to COVID-19 as well as many other lung conditions.
*The following are important statements regarding the use of this tool:
Volumetric histogram and lung segmentation functionality are FDA cleared features of Intuition. This functionality is not FDA cleared specifically for COVID-19. It must only be used as an aid and that final interpretation should be performed by a licensed healthcare practitioner with the appropriate training.
The results should not be used for screening and the software does not provide specific disease detection and should not be solely or primarily relied upon to diagnose or treat COVID-19.
This device is not indicated for the diagnosis of COVID-19 and that in vitro diagnostic testing is currently the only definitive method to diagnose COVID-19.
This tool is available by specific licenses only.
The default thresholds are generalized recommendations and limits for device performance when used in an U.S. population. The image analysis should only be used as an aid and the final interpretation should be performed by a licensed healthcare practitioner with the appropriate training.